Experimental antibody takes on brain cancer in tiny trial
NCT ID NCT06922604
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a drug called glofitamab, given after a pre-treatment with obinutuzumab, in 20 adults with central nervous system lymphoma. The goal is to check safety and side effects. Glofitamab is a bispecific antibody that helps the immune system attack cancer cells. The study is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Glofitamab (a bispecific antibody) with obinutuzumab pre-treatment
What this could lead to
If it works, this could point toward a new treatment option for central nervous system lymphoma, a hard-to-treat cancer.
What could go wrong
This is a very early phase 1b trial with only 20 participants, focused on safety. It may not show enough benefit or could have serious side effects like cytokine release syndrome or nerve toxicity.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact